*2.2.2.2 Off-label uses*

Although the FDA has not recognized or approved these applications of SNM, there is a growing body of evidence that demonstrates its effectiveness in other genitourinary pathological conditions. In particular are chronic pelvic pain disorders including both IC/BPS and non-IC chronic pelvic pain syndrome (CPPS). Despite lack of availability of high-level evidence, the off-label application of SNM in these conditions continues with variable results in improving associated urinary symptoms and quality of life parameters.

Other non-approved applications of SNM include its use in special populations such as those with neurogenic lower urinary tract symptoms, pediatrics and adolescents, and even in contraindicated situations including continued SNM in pregnancy for women with urological conditions. Most of these applications carry hypothetical risks, a spectrum of which have been refuted in small case series and reports in literature, but bigger studies are needed to elucidate and clarify the role of SNM in these situations.
